X4 Pharmaceuticals Secures EU Approval, Eyes €226m Milestones and Full Phase 3 Enrollment
XFOR•X4 Pharmaceuticals reported Q1 net loss of $20.2m on $2.7m revenue versus $28.8m a year earlier and held $233.7m cash. The 4WARD Phase 3 chronic neutropenia trial spans over 110 sites with full enrollment due by end-Q3 and EU approval unlocks up to €226m.
1. Q1 Financial Results
X4 Pharmaceuticals reported a net loss of $20.2 million ($0.16 per share) for Q1 2026 on revenue of $2.7 million, down from $28.8 million a year earlier due to absence of €27.9 million license revenue. R&D expenses declined to $15.5 million and G&A to $7.0 million following a 2025 restructuring.
2. Phase 3 Trial Progress
The global 4WARD Phase 3 trial for mavorixafor in chronic neutropenia has expanded to over 110 active sites, including more than 20 in the U.S., and remains on track to complete enrollment of 176 patients by end-Q3 2026, supported by targeted medical affairs and data-driven referral initiatives.
3. EU Approval and Partnership Terms
The European Commission granted marketing authorization for XOLREMDI (mavorixafor) as the first treatment for WHIM syndrome in the EU, with commercialization led by partner Norgine. X4 stands to receive up to €226 million in contingent milestones plus escalating mid-twenties percent royalties on future net sales in licensed territories.
4. Cash Runway and Outlook
As of March 31, 2026, X4 held $233.7 million in cash, providing runway through 2028. Management remains focused on completing Phase 3 enrollment, transitioning EU marketing authorization to Norgine, and advancing mavorixafor development in rare hematologic disorders.
